Pathway Genomics’ Laboratory Director Honorary Speaker at 2014 National Women’s Survivors Convention - Pathway Genomics
Pathway Genomics is proud to celebrate 10 successful years as a CLIA and CAP accredited clinical laboratory!

Pathway Genomics’ Laboratory Director Honorary Speaker at 2014 National Women’s Survivors Convention

SAN DIEGO, CAAugust 5, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced its laboratory director, Dr. Linda Wasserman, was an honorary speaker at the second annual National Women’s Survivors Convention. Held last week in Nashville, Tennessee, the convention serves as a place for women survivors of cancer to come together over issues surrounding survivorship. The purpose of the convention is to help women re-enter their lives by supporting, educating, and connecting them with other women whose lives have been touched by cancer. This year’s convention hosted more than 800 people affected by cancer.

Titled “Genetic Testing: How Can It Help My Family and Me?,” Dr. Wasserman’s talk focused on indications for genetic testing for cancer risk and what is involved. She discussed the benefits and risks, as well as how cancer patients and their families can use the information.

“I was delighted to have the opportunity to present and share my experience with people at this convention. Genetic testing is a vital component in assessing cancer risk, and we are at a time in medical care where this information is becoming more and more accessible.” said Dr. Wasserman. “Our ultimate goal as a clinical laboratory is to ensure all people who need BRCA testing get it, regardless of how much money they have.”


Dr. Wasserman is the former medical and laboratory director of the Molecular Genetics Laboratory at UC San Diego. She established and directed the DNA Sequencing and Molecular Pathology laboratories within the UCSD Moores Cancer Center.

Over the last two months, Pathway Genomics has launched a leading-edge next-generation sequencing BRCA1/2 test, called BRCATrueTM, and co-hosted a fundraiser benefiting Susan G. Komen that raised more than $300,000 for the organization. The company also unveiled its BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need through participating health care providers, up to $10 million of free testing. It is the only program of its kind in the history of the medical community. Pathway Genomics also has a very competitive and patient-friendly financial assistance program for patients who cannot afford testing.